ArticleReumatologia2025
What are the characteristics of paradoxical effects in the Biotherapies Registry of the Moroccan Society of Rheumatology?
Article in Reumatologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The main objective of our study was to assess the prevalence of paradoxical reactions in patients with chronic inflammatory rheumatism treated with biologic drugs, while secondary objectives were to determine the type of paradoxical reactions and to investigate associated factors. Material and methods: We conducted a descriptive cohort study using 36-month frozen data from the RBSMR registry. This is a registry promoted by the Moroccan Society of Rheumatology, including patients treated for rheumatoid arthritis (RA) or spondyloarthritis treated with a biologic drug. The paradoxical reaction was defined by the appearance of a pathology that could be treated by biological drugs. We investigated the prevalence of paradoxical reactions, and the factors associated with their occurrence. Statistical analysis was performed using JAMOVI software. Results: We analyzed 440 patients in the RBSMR. Paradoxical reactions were found in 19 patients (4.6%). The mean time to onset of paradoxical manifestations was 30 weeks (1-144 weeks). Uveitis was the most frequent paradoxical reaction, found in 9 patients, followed by psoriasis in 7 patients, and then pyoderma gangrenosum, lichen, and granulomatous dermatitis in only 1 patient each. These paradoxical effects were found predominantly in men (57.9% of cases). Etanercept was the most prescribed biologic, in 52.6% of patients with paradoxical reactions, followed by adalimumab in 21.1%, golimumab in 15.8%, and secukinumab in 5.3%. Permanent discontinuation of biological treatment was recommended for all patients. In univariate analysis, the occurrence of a paradoxical effect was related to sex ( Conclusions: Our study suggests that there is a low prevalence of paradoxical effects in our population. However, these are reactions that need to be identified and investigated to improve the management of our patients with chronic inflammatory rheumatism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.